Akèy › Maladi Greff-versus-host
Etid klinik pou Maladi Greff-versus-host ap rekrite nan Etazini
34 etid pou Maladi Greff-versus-host ap rekrite patisipan nan sit atravè Etazini.
Vil ki gen plis etid
- Boston, MA10 etid
- New York City, NY7 etid
- Columbus, OH6 etid
- Washington, DC5 etid
- Atlanta, GA5 etid
- Queens, NY4 etid
- St. Louis, MO4 etid
- Seattle, WA4 etid
- Miami, FL4 etid
- Portland, OR4 etid
- Detroit, MI4 etid
- Pittsburgh, PA4 etid
- Baldwin Park, CA4 etid
- Tampa, FL4 etid
- Staten Island, NY3 etid
- Greenburgh, NY3 etid
- East Norwalk, CT3 etid
- New Rochelle, NY3 etid
- Edison, NJ3 etid
- Los Angeles, CA3 etid
- Chicago, IL3 etid
- Cleveland, OH3 etid
- Nashville, TN3 etid
- Houston, TX3 etid
Pa eta
- Florid7 etid
- Georgia5 etid
- Illinois3 etid
- Kalifòni9 etid
- Kansas3 etid
- Maryland5 etid
- Massachusetts10 etid
- Michigan5 etid
- Missouri4 etid
- New Jersey4 etid
- New York10 etid
- Ohio7 etid
- Oregon4 etid
- Pennsylvania6 etid
- Tennessee3 etid
- Texas4 etid
- Washington4 etid
Etid ki fèk mete ajou
Tèks ofisyèl etid la (Anglè)
Vulvovaginal Graft-versus-Host Disease: Diagnosis and Microbiome Evaluation
Ap rekriteEtid obsèvasyon
Laj 18 a 70 · Fanm · Mizajou Sep 29, 2026 · NCT06649201Phase I/II Study of Pacritinib, A JAK2/IRAK1/CSF1R Inhibitor, in Refractory Chronic Graft-Versus-Host Disease (cGVHD) After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)
Ap rekriteFaz 1/2
Laj 18 a 120 · Tout sèks · Mizajou Sep 28, 2026 · NCT05531786Multidisciplinary Intervention for Adults With Chronic Graft-versus-host Disease
Ap rekrite
Laj 18 ak plis · Tout sèks · Mizajou Sep 24, 2026 · NCT06910969Evaluation of Patients With Immune Function Abnormalities
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Tout laj · Tout sèks · Mizajou Sep 22, 2026 · NCT00128973Long-term Evaluation and Follow-up Care of Patients Treated With Stem Cell Transplants
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 7 a 80 · Tout sèks · Mizajou Sep 1, 2026 · NCT00106925Vitamin A Supplementation in Allogeneic Stem Cell Transplantation.
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Aug 24, 2026 · NCT06450925Dose-Escalation Trial of Mesenchymal Stromal Cells in Patients With Medical Xerostomia
Ap rekriteFaz 1
Laj 18 a 90 · Tout sèks · Mizajou Aug 19, 2026 · NCT06392711Thiotepa-based Conditioning Regimen With De-escalated Post-graft Cyclophosphamide for Allogeneic Stem Cell Transplantation in Hematologic Malignancies
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Aug 18, 2026 · NCT07565220Improved Methods of Cell Selection for Bone Marrow Transplant Alternatives
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 18 a 60 · Tout sèks · Mizajou Aug 7, 2026 · NCT00001529Ex Vivo-Expanded Regulatory T Cells Plus Low-Dose Interleukin-2 for Steroid-Refractory Chronic GVHD
Ap rekriteFaz 1
Laj 2 ak plis · Tout sèks · Mizajou Jul 23, 2026 · NCT06991361Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Jul 7, 2026 · NCT07216443A Study of Ruxolitinib for Preventing Graft-Versus-Host Disease in People With a Hematologic Malignancy Who Will Receive a Stem Cell Transplant
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Jul 7, 2026 · NCT07359859Emapalumab With Post-Transplant Cyclophosphamide, Tacrolimus and Mycophenolate Mofetil for the Prevention of Graft-versus-Host Disease After Donor Reduced-Intensity Hematopoietic Cell Transplant
Ap rekriteFaz 1
Laj 18 a 75 · Tout sèks · Mizajou Jul 1, 2026 · NCT06996119A Study of Belumosudil in People at Risk of Developing Graft-Versus-Host Disease After a Stem Cell Transplant
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Jun 29, 2026 · NCT07006506Vedolizumab Plus Post-transplant Cyclophosphamide and Short Course Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation After Reduced Intensity Conditioning
Ap rekriteFaz 2
Laj 18 a 80 · Tout sèks · Mizajou Jun 29, 2026 · NCT06815003A Study of Axatilimab at 3 Different Doses in Participants With Chronic Graft Versus Host Disease (cGVHD)
Ap rekriteFaz 2
Laj 2 ak plis · Tout sèks · Mizajou Jun 16, 2026 · NCT04710576Post-Transplant Cyclophosphamide, Bortezomib and Abatacept for the Prevention of Graft-versus-Host-Disease (GvHD)
Ap rekriteFaz 1/2
Laj 14 a 100 · Tout sèks · Mizajou May 29, 2026 · NCT05289167A Study of Photobiomodulation (PBM) Therapy in People With Oral Graft-Versus-Host Disease (GVHD) After Stem Cell Transplant
Ap rekriteFaz 2
Laj 4 ak plis · Tout sèks · Mizajou May 22, 2026 · NCT05675930A Study of Tacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (BMT CTN 2203)
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou May 20, 2026 · NCT06615050Cord Blood Transplantation in Children and Young Adults With Blood Cancer
Ap rekriteFaz 2
Jiska laj 26 · Tout sèks · Mizajou May 14, 2026 · NCT07566377Extended vs Short-term Abatacept Dosing for Graft Versus Host Disease Prophylaxis
Ap rekriteFaz 2
Laj 2 ak plis · Tout sèks · Mizajou May 11, 2026 · NCT04380740Ruxolitinib With and Without CTLA-4 Ig Abatacept for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Apr 22, 2026 · NCT06008808Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Apr 15, 2026 · NCT07356245Phase I/II Study of AD-PluReceptor Plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients With Autoimmune Disorders
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Apr 15, 2026 · NCT06434363A Feasibility Study Using CLINIMACS® for Alpha/Beta T-Cell Depletion in Stem Cell Transplant
Ap rekrite
Jiska laj 30 · Tout sèks · Mizajou Apr 13, 2026 · NCT04337515Sous ClinicalTrials.gov, done yo ranmase Oct 1, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.